CompletedPhase 1NCT02216890
Safety Study of SGN-CD70A in Cancer Patients
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen Inc.
- Principal Investigator
- Elaina Gartner, MDSeagen Inc.
- Intervention
- SGN-CD70A(drug)
- Enrollment
- 38 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2017
Study locations (17)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester, New York, United States
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
- University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
- Case Western Reserve University / University Hospitals Case Medical Center, Cleveland, Ohio, United States
- University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States
- Texas Oncology - Austin Midtown, Austin, Texas, United States
- Methodist Cancer Center, Houston, Texas, United States
- University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02216890 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →